Rexall Osteo-Bi-Flex 27% Sales Growth Paces Strong FY 1999 Results
This article was originally published in The Tan Sheet
Executive Summary
Sales of Rexall Sundown's Osteo-Bi-Flex joint health brand for the year ended Aug. 31 were roughly $103 mil., up 27% over the prior year, the company said in a conference call to securities analysts Sept. 30.
You may also be interested in...
Rexall Sundown Cellasene Sales Reach $35 Mil. In Third Quarter
Reflecting retailers' initial pipeline purchases, sales of the Cellasene cellulite-reducing dietary supplement were $35 mil. for the fiscal third quarter (ended May 31), an "all-time record" for the company, Rexall Sundown said during a June 15 teleconference. Initial Cellasene sales exceeded the firm's previous record of $32 mil. for Osteo Bi-Flex in the fourth quarter of fiscal 1998.
Rexall Sundown
Advertising Osteo Bi-Flex glucosamine/chondroitin dietary supplement in Arthritis Foundation "Help is in your grasp" magazine brochure insert. The supplement marketer also has made a $125,000 general donation to the foundation and is using the AF logo in other advertising along with a statement disclosing its funding of the group. The educational brochure, with warnings signs for osteoarthritis and tips for living with the condition, is in May Reader's Digest "mature" circulation and large print issues as well as New Choices magazine. Other advertisers include McNeil Consumer Healthcare (Tylenol), Pfizer (Ultra Strength Bengay) and Searle (Rx Celebrex). Ads in the leaflet bear the "Help is in your grasp" insignia with the Arthritis Foundation logo in the center
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC